ADMA Biologics Inc (ADMA) has disclosed a new risk, in the Regulation category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ADMA Biologics Inc. faces significant business risks that could impact its stock value, as highlighted in their quarterly report. The summary of risk factors indicates that investing in their common stock is speculative due to various principal factors. These risks are detailed further in the report under ‘Risk Factors’ and should be reviewed alongside other information provided. Investors are advised to carefully consider these risks before making investment decisions.
Overall, Wall Street has a Moderate Buy consensus rating on ADMA stock based on 2 Buys.
To learn more about ADMA Biologics Inc’s risk factors, click here.